Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
19 July 2021 | Story Lunga Luthuli | Photo Supplied
Fletcher Hiten, Chief Bioanalyst at FARMOVS, next to Aurora.

The Bioanalytical Services Division (BASD) at FARMOVS comprises a group of skilled and passionate scientists involved in the quantification of drugs, metabolites, and biomarkers in various biological matrices. One of their Analytical Science experts, Fletcher Hiten, explains what sets their team apart from the rest.

“Over the past 47 years, we have developed almost 600 validated assay methods. Most of these methods are for the analysis of ‘small’ molecules using chromatographic techniques such as LC-MS/MS, GC-MS, and HPLC, although LC-MS/MS is the technique of choice. New bioanalytical assays are continuously being development and validated in adherence to international regulatory guidelines set by the US-FDA and European Medicines Agency (EMA),” says Hiten.

“Recently, we decided to enhance our capabilities by recruiting exceptional talent. The newest member of the FARMOVS team is Aurora, a SCIEX Triple Quad™ 7500 LC-MS/MS mass analyser. Aurora is Latin for ‘dawn’: the beginning of a new era, especially one considered favourable. The SCIEX 7500 is currently marketed as the most sensitive triple quadrupole mass spectrometer available, allowing for sub-picogram/ml quantification. This means that Aurora will set FARMOVS apart from other clinical research organisations (CROs), creating an exciting and favourable landscape for clients to explore new partners in research.” 

Hiten stated: “If there was ever a time to move your next study to FARMOVS, it is now. To have Aurora on our team has many advantages, given that our clients can access unprecedented analytical sensitivity, which enables the quantification of pharmacokinetic (PK) profiles of drugs that have very low systemic absorption. These include predominantly local acting drugs, such as plasma concentrations of respiratory drugs (e.g., tiotropium and ipratropium), topically applied creams and ointments, and ophthalmology drops with ultra-sensitivity.”

“In addition, the quantification of drugs in low-volume matrices will also be exponentially enhanced, enabling the quantification of body fluids, where only a few microlitres can be collected, for example vaginal fluid, dried blood spots, cerebrospinal fluid, aqueous humour, synovial fluid, and epidermal micro-dialysis lysate – to name a few. The quantification of absorbed exogenous drugs into tissue, like vaginal biopsies and hair follicles, is also possible,” added Hiten. 

“And finally, multiple analyte analysis. In this case, the collected blood sample needs to be split into multiple aliquots for analysis, for example drug-drug interaction (DDI) studies with the Basel cocktail. The smaller sample volumes will allow more frequent sampling to be feasible and thus more accurate DDI interpretation,” Hiten explains.

“As a bio-analyst, one is seldom surprised. However, Aurora has already opened doors to new frontiers for our entire team and we cannot wait to do some more exploration,” says Hiten. 

To find out more about what Aurora and the FARMOVS team can do for your study, email business@farmovs.com

News Archive

UFS team helps a pupil to hear again
2014-01-24

 

“I was scared at first. I could not remember the sound of my own voice. Being Deaf -it was like living on another planet.”

These are the words of the 18-year-old Andile (Godfrey) Jantjies after he heard sounds and words for the first time in almost 12 months.

Andile, a former pupil at the Albert Moroka School in Thaba Nchu, was the recipient of a cochlear implantation under the Bloemfontein Cochlear Implant Programme (BCIP) run by the Department of Otorhinolaryngology at the University of the Free State.

Andile lost his hearing after contracting bacterial meningitis in June 2013. This resulted in bilateral profound deafness and despite his good academic record, his school refused to have him enrolled for 2014.

The cochlear implant was inserted in October 2013 and was switched on for the first time on Thursday 23 January 2014.

“I want to go back immediately,” Andile said excitedly after gradually becoming comfortable with hearing his own and other voices.

Dr Iain Butler from the Department of Otorhinolaryngology says cases like Andile’s are a medical emergencies due to the fact that meningitis causes the inner ear to become replaced by bone.

“This can occur after as little as four months after the infection and means that the insertion of a cochlear implant becomes impossible.

A cochlear implant system costs approximately R220 000.

It converts sounds/speech into electrical signals that directly stimulate the auditory nerve, bypassing the damaged inner ear. It is indicated for babies with congenital hearing loss, as well as acquired hearing loss in children or adults. It requires intensive rehabilitation in order to learn to hear again, and most recipients develop very good hearing. Andile now has the opportunity to hear again, continue his schooling and become an economically independent member of society, rather than being dependent on others.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept